{
    "info": {
        "nct_id": "NCT05485974",
        "official_title": "A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation",
        "inclusion_criteria": "Key Inclusion Criteria:\n\nMale or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures\n\nAdvanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing\n\nMust have failed or refused standard of care therapy, are not eligible for standard of care therapy, or cannot benefit from standard of care therapy, in the opinion of the Investigator\n\nAt least 1 measurable target lesion that meets the definition of RECIST v1.1\n\nECOG Performance Status of 0 or 1\n\nDemonstrate adequate organ function\n\nExpected survival time > 3 months in the opinion of the investigator\n\nMust be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Key Exclusion Criteria:\n\nHistory of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is <5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled\n\nUntreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks\n\nClinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first dose of HBI-2438; or the presence of unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher\n\nAny unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration\n\nActive autoimmune diseases or history of autoimmune diseases that may relapse\n\nPregnant or nursing\n\nPrior treatment with any KRAS G12C inhibitors\n\nAny condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication â‰¤14 days before the first study treatment administration\n\nTreatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "ECOG Performance Status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have failed or refused standard of care therapy, are not eligible for standard of care therapy, or cannot benefit from standard of care therapy, in the opinion of the Investigator",
            "criterions": [
                {
                    "exact_snippets": "Must have failed ... standard of care therapy",
                    "criterion": "standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior failure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refused standard of care therapy",
                    "criterion": "standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior refusal",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are not eligible for standard of care therapy",
                    "criterion": "standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "cannot benefit from standard of care therapy, in the opinion of the Investigator",
                    "criterion": "standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "potential benefit (per Investigator)",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Advanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing",
            "criterions": [
                {
                    "exact_snippets": "Advanced malignant solid tumors",
                    "criterion": "malignant solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS G12C mutation- as determined by genetic testing",
                    "criterion": "KRAS G12C mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": "genetic testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption",
            "criterions": [
                {
                    "exact_snippets": "Must be able to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have gastrointestinal abnormalities that significantly affect drug absorption",
                    "criterion": "gastrointestinal abnormalities affecting drug absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Demonstrate adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "At least 1 measurable target lesion that meets the definition of RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "At least 1 measurable target lesion",
                    "criterion": "measurable target lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meets the definition of RECIST v1.1",
                    "criterion": "target lesion RECIST v1.1 definition",
                    "requirements": [
                        {
                            "requirement_type": "RECIST v1.1 criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Expected survival time > 3 months in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Expected survival time > 3 months",
                    "criterion": "expected survival time",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator opinion on expected survival time",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "investigator opinion"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "Pregnant or nursing",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks",
            "criterions": [
                {
                    "exact_snippets": "Untreated or symptomatic central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "no untreated metastases"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "no symptomatic metastases"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks",
                    "criterion": "CNS metastases (asymptomatic, treated)",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "steroid requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration",
                    "criterion": "treatment with other investigational drugs/devices",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment administration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Prior treatment with any KRAS G12C inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any KRAS G12C inhibitors",
                    "criterion": "prior treatment with KRAS G12C inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Active autoimmune diseases or history of autoimmune diseases that may relapse",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune diseases",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of autoimmune diseases that may relapse",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relapse risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy",
                    "criterion": "toxicity from previous anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 4 weeks of first study treatment administration",
                    "criterion": "time since previous anti-cancer therapy toxicity",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first dose of HBI-2438; or the presence of unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke or myocardial infarction within 6 months prior to first dose of HBI-2438",
                    "criterion": "history of stroke or myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timing reference",
                            "expected_value": "prior to first dose of HBI-2438"
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure of New York Heart Association Grade 2 or higher",
                    "criterion": "congestive heart failure NYHA grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Any condition that required systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication â‰¤14 days before the first study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication â‰¤14 days before the first study treatment administration",
                    "criterion": "systemic treatment with corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before the first study treatment administration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic treatment with ... other immunosuppressive medication â‰¤14 days before the first study treatment administration",
                    "criterion": "systemic treatment with other immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before the first study treatment administration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is <5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled",
            "criterions": [
                {
                    "exact_snippets": "History of another concurrent malignancy within 3 years prior to study entry",
                    "criterion": "history of another concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the malignancy was treated with curative intent",
                    "criterion": "treatment of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "likelihood of relapse is <5% in 2 years",
                    "criterion": "likelihood of relapse of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "relapse risk",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "% in 2 years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled",
                    "criterion": "history of specific prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "malignancy type",
                            "expected_value": [
                                "squamous cell carcinoma of the skin",
                                "basal cell carcinoma of the skin",
                                "carcinoma in situ of the cervix"
                            ]
                        },
                        {
                            "requirement_type": "enrollment eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Key Inclusion Criteria:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Key Exclusion Criteria:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}